Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Failed ANDA Bioequivalence Studies Haven’t Impacted Review Decisions, FDA Says

Executive Summary

Bioequivalent studies that fail to show bioequivalence between a generic drug and its reference product have not been a factor in ANDA approvals, Barbara Davit, acting director of the Office of Generic Drugs’ Division of Bioequivalence 2, reported at the Generic Pharmaceuticals Association’s fall technical meeting on Oct. 5 in Bethesda, Md.
Advertisement

Related Content

Generics Joining the 12-Month Stability Data Club, But 'When?' Is Big Question
Generics Joining The 12-Month Stability Data Club, But “When?” Is Big Question
Generics Joining The 12-Month Stability Data Club, But “When?” Is Big Question
Generics Joining The 12-Month Stability Data Club, But “When?” Is Big Question
ANDA Complete Response Letters To Become Routine In 2012

Topics

Advertisement
UsernamePublicRestriction

Register

PS053887

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel